Novartis and the National Health Service in England have struck a deal on Kymriah (tisagenlecleucel) for use in children and young people with a certain form of leukemia, marking the first time a European country has agreed to fund access to a CAR-T therapy.
Announced today, the agreement comes less than 10 days after Novartis became one of the first two companies to receive...